Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor.
Adult
Arsenic Trioxide
/ pharmacology
Base Sequence
Brain
/ drug effects
Brain Neoplasms
/ drug therapy
Cell Line, Tumor
Child, Preschool
Chromosome Aberrations
DNA Methylation
/ genetics
Female
Germ-Line Mutation
/ genetics
Humans
Insulin-Like Growth Factor I
/ metabolism
Molecular Targeted Therapy
Neoplasms, Neuroepithelial
/ drug therapy
Principal Component Analysis
Pyrimidines
/ pharmacology
Receptor, Notch1
/ metabolism
Sulfones
/ pharmacology
Transcriptome
/ genetics
Tumor Suppressor Protein p53
/ genetics
ATO
IGF
NOTCH1
SHH
WNT
ceritinib
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
30 Aug 2019
30 Aug 2019
Historique:
received:
05
07
2019
revised:
15
08
2019
accepted:
28
08
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
22
1
2020
Statut:
epublish
Résumé
The insulin-like growth factor (IGF) pathway plays an important role in several brain tumor entities. However, the lack of inhibitors crossing the blood-brain barrier remains a significant obstacle for clinical translation. Here, we targeted the IGF pathway using ceritinib, an off-target inhibitor of the IGF1 receptor (IGF1R) and insulin receptor (INSR), in a pediatric patient with an unclassified brain tumor and a
Identifiants
pubmed: 31480400
pii: ijms20174267
doi: 10.3390/ijms20174267
pmc: PMC6747232
pii:
doi:
Substances chimiques
NOTCH1 protein, human
0
Pyrimidines
0
Receptor, Notch1
0
Sulfones
0
Tumor Suppressor Protein p53
0
Insulin-Like Growth Factor I
67763-96-6
ceritinib
K418KG2GET
Arsenic Trioxide
S7V92P67HO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Cancer Res. 2002 Jun;8(6):1822-30
pubmed: 12060623
Eur J Clin Pharmacol. 2002 Nov;58(8):521-6
pubmed: 12451429
J Biol Chem. 2003 Aug 22;278(34):31564-73
pubmed: 12771153
Am J Pathol. 2003 Nov;163(5):1721-7
pubmed: 14578171
Trends Pharmacol Sci. 2004 Aug;25(8):423-9
pubmed: 15276711
Science. 2004 Oct 8;306(5694):269-71
pubmed: 15472075
Exp Cell Res. 2005 Jan 15;302(2):281-91
pubmed: 15561108
Am J Pathol. 2005 Apr;166(4):1153-62
pubmed: 15793295
Nature. 2005 Sep 8;437(7056):270-4
pubmed: 16025100
J Clin Oncol. 2006 Nov 20;24(33):5223-33
pubmed: 17114655
Cancer Cell. 2008 Mar;13(3):249-60
pubmed: 18328428
Nat Genet. 2008 Sep;40(9):1130-5
pubmed: 19165927
Neurosignals. 2009;17(1):55-70
pubmed: 19212140
J Clin Oncol. 2009 Apr 10;27(11):1884-92
pubmed: 19289631
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6315-20
pubmed: 19325125
Leuk Res. 2010 Mar;34(3):403-5
pubmed: 19733394
Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22293-8
pubmed: 20007775
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Acta Oncol. 2011 Apr;50(3):441-7
pubmed: 20698809
J Clin Invest. 2011 Jan;121(1):148-60
pubmed: 21183792
J Clin Invest. 2011 Feb;121(2):508-9
pubmed: 21266769
Future Med Chem. 2009 Sep;1(6):1153-71
pubmed: 21425998
Genome Biol. 2011 Aug 11;12(8):R72
pubmed: 21835007
Cancer Cell. 2011 Sep 13;20(3):384-99
pubmed: 21907928
Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17761-6
pubmed: 22006338
Expert Opin Ther Targets. 2012 Dec;16(12):1227-38
pubmed: 22992192
Ann Oncol. 2013 Mar;24(3):784-91
pubmed: 23104723
P T. 2012 Dec;37(12):670-82
pubmed: 23319845
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
J Med Chem. 2013 Jul 25;56(14):5675-90
pubmed: 23742252
Cancer Res. 2013 Sep 1;73(17):5381-90
pubmed: 23852537
Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5
pubmed: 24234437
Acta Neuropathol. 2014 Apr;127(4):609-11
pubmed: 24562983
N Engl J Med. 2014 Mar 27;370(13):1189-97
pubmed: 24670165
Nat Rev Drug Discov. 2014 Jul;13(7):513-32
pubmed: 24981364
Nat Methods. 2014 Nov;11(11):1138-1140
pubmed: 25262207
Nat Rev Clin Oncol. 2015 Aug;12(8):445-64
pubmed: 25850553
Circ Cardiovasc Genet. 2015 Aug;8(4):572-581
pubmed: 25963545
Neuro Oncol. 2016 Jan;18(1):48-57
pubmed: 26136493
Front Oncol. 2015 Jul 08;5:142
pubmed: 26217584
Pharmacol Res. 2015 Dec;102:200-7
pubmed: 26361725
Mol Endocrinol. 2015 Nov;29(11):1549-57
pubmed: 26366975
N Engl J Med. 2015 Dec 10;373(24):2336-2346
pubmed: 26580448
Am J Pathol. 2016 Feb;186(2):435-45
pubmed: 26687816
Blood Rev. 2016 May;30(3):201-11
pubmed: 26709030
EBioMedicine. 2015 Dec 12;3:54-66
pubmed: 26870817
Cancer Chemother Pharmacol. 2016 Apr;77(4):829-37
pubmed: 26972330
Lancet Oncol. 2016 Apr;17(4):452-463
pubmed: 26973324
Cancer Cell. 2016 Apr 11;29(4):508-522
pubmed: 27050100
Cancer Lett. 2016 Oct 28;381(2):287-95
pubmed: 27521572
Oncotarget. 2016 Sep 20;7(38):61860-61873
pubmed: 27556362
Int J Oncol. 2016 Nov;49(5):2135-2146
pubmed: 27665785
Oncotarget. 2016 Dec 13;7(50):83378-83391
pubmed: 27825128
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Drug Des Devel Ther. 2017 Jul 05;11:2047-2063
pubmed: 28740365
Target Oncol. 2017 Oct;12(5):571-597
pubmed: 28815409
Oncotarget. 2017 Sep 1;8(41):69295-69302
pubmed: 29050204
Target Oncol. 2017 Dec;12(6):815-826
pubmed: 29067644
Oncotarget. 2017 Sep 6;8(46):81501-81510
pubmed: 29113409
Medicine (Baltimore). 2017 Nov;96(45):e8652
pubmed: 29137103
Am J Surg Pathol. 2019 Jan;43(1):56-63
pubmed: 29266023
Oncotarget. 2017 Dec 11;8(69):114210-114225
pubmed: 29371980
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Int J Mol Sci. 2019 Jun 21;20(12):null
pubmed: 31234291
Ann N Y Acad Sci. 1993 Aug 27;692:33-43
pubmed: 8215043